Mastitis Market Players, Comprehensive Study Explores Huge Revenue Scope in Future by 2030

Comments · 94 Views

Mastitis Market size is predicted to grow at a compound annual growth rate of a CAGR of 16.20 % from 2021 to 2030, reaching USD 53,148.44 million.

According to recent reports, the Mastitis Market size is predicted to grow at a compound annual growth rate of a CAGR of 16.20 % from 2021 to 2030, reaching USD 53,148.44 million. 

Mastitis is a form of infection that occurs is the tissue of one or both mammary glands present inside the breast and causes inflammation, swelling, and tenderness of the breast tissues. It is a common occurrence caused due to a blocked duct among breastfeeding women. There is a high chance of women suffering from breast cancer to contract mastitis.

Multiple factors are expected to influence the market. The World Cancer Research Fund refers to breast cancer as the most common type of cancer in women globally, and second-most common cancer overall. In 2018, The WCRF also registered more than 2 million new cases of breast cancer.

The influential factors driving the Global Mastitis Market are the constant changes in modern lifestyle, dietary habits, among others, which subsequently increase the risk of breast cancer. The increasing awareness and government efforts to initiate awareness about both – human, and bovine mastitis are expected to contribute substantially to the growth of the global mastitis market over the forecast period.

Segmental Analysis

The Global Mastitis Market is segmented based on type, treatment, end-user, and region.

Based on type, the market has been segmented into human mastitis and bovine mastitis. The human mastitis segment is further segmented into non-infectious mastitis and infectious mastitis. The bovine mastitis is further segmented into contagious mastitis, environmental mastitis, and opportunist mastitis.

Based on treatment, the mastitis market has been segmented into antibiotics, pain relievers, surgery, vaccines, and others.

Based on end-user, the mastitis market has been segmented into hospitals and clinics, veterinary centers, and others. The hospital and clinics segment is expected to account for the largest market share over the forecast period, followed by the veterinary centers segment.

Regional Analysis

Based on the region, the market has been segmented into the Americas, Europe, Asia-Pacific, and Middle East Africa.

The Americas account for the dominant region in the global mastitis market, owing primarily to the increase in expenditure on healthcare, and the established medical infrastructure in North America. Additionally, the growing prevalence of bovine mastitis in the region is expected to drive the market over the forecast period.

Europe is the second leading region in the global mastitis market, owing to the vast patient pool afflicted with breast cancer affected the patient population, availability of superior quality medical facilities, government initiatives to spread awareness about breast cancer and healthy breastfeeding, and the growing expenditure to enhance the healthcare sector. These factors are expected to influence the market positively over the forecast period,

The Asia Pacific region is assessed to witness substantial growth over the forecast period, owing to the increase in government initiatives and expenditure, in emerging economies such as China and India to improve the healthcare sector and provide consumers with high-quality medical facilities. 

The Middle East and Africa region are expected to register the smallest market share, owing to the poor healthcare infrastructure in Africa. The Middle East is likely to contribute to the majority of the market share over the forecast period, owing to emerging economies such as Saudi Arabia, and the United Arab Emirates. The gradually increasing awareness about breast cancer is expected to drive the market in this region.

The major profiled by MRFR in the report on the Mastitis Market Players are:

Apthera Inc. (U.K.)

Astellas Pharma Inc. (Japan)

Bayer AG (Germany)

BioNumerik Pharmaceuticals Inc. (U.S.)

Boehringer Ingelheim GmbH (Germany)

  1. Hoffmann-La Roche Ltd. (Switzerland)

Merck Co Inc. (U.S.)

Novartis AG (Switzerland)

Oncogenex (U.S.)

Oncothyreon Inc. (U.S.)

Pfizer Inc. (U.S.)

Sanofi S.A. (France)

Zoetis Inc. (U.S.)

About US:
Market Research Future (MRFR), enable customers to unravel the complexity of various industries through Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research Consulting Services.

Comments